407 related articles for article (PubMed ID: 29879463)
1. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases.
Xie W; Song X; Liu Z
Vascul Pharmacol; 2018 Oct; 109():17-26. PubMed ID: 29879463
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Koska J; Sands M; Burciu C; Reaven P
Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
Balakumar P; Dhanaraj SA
Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
Secrest MH; Udell JA; Filion KB
Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
[TBL] [Abstract][Full Text] [Related]
5. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety.
Green JB
Postgrad Med; 2012 Jul; 124(4):54-61. PubMed ID: 22913894
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of the DPP-4 inhibitors.
Jose T; Inzucchi SE
Diab Vasc Dis Res; 2012 Apr; 9(2):109-16. PubMed ID: 22337893
[TBL] [Abstract][Full Text] [Related]
7. DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.
Bae EJ
Arch Pharm Res; 2016 Aug; 39(8):1114-28. PubMed ID: 27502601
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Thornberry NA; Gallwitz B
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
[TBL] [Abstract][Full Text] [Related]
9. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
Santamarina M; Carlson CJ
BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Fadini GP; Avogaro A
Vascul Pharmacol; 2011; 55(1-3):10-6. PubMed ID: 21664294
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.
Chrysant SG; Chrysant GS
Am J Cardiol; 2012 Jun; 109(11):1681-5. PubMed ID: 22425330
[TBL] [Abstract][Full Text] [Related]
12. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
Davidson MH
Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
[TBL] [Abstract][Full Text] [Related]
13. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.
Kim NH; Yu T; Lee DH
Biomed Res Int; 2014; 2014():368703. PubMed ID: 25140306
[TBL] [Abstract][Full Text] [Related]
14. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
16. DPP-4 inhibitors in the treatment of type 2 diabetes.
Duez H; Cariou B; Staels B
Biochem Pharmacol; 2012 Apr; 83(7):823-32. PubMed ID: 22172989
[TBL] [Abstract][Full Text] [Related]
17. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Cardiovascular Injury in Type 2 Diabetes and Potential Effects of Dipeptidyl Peptidase-4 Inhibition.
Dokken B
J Cardiovasc Nurs; 2016; 31(3):274-83. PubMed ID: 25829138
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
20. New Therapeutic Strategies for Type 2 Diabetes
Yehya A; Sadhu AR
Methodist Debakey Cardiovasc J; 2018; 14(4):281-288. PubMed ID: 30788014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
